每经AI快讯，1月30日，科兴制药(688136.SH)公告称，预计2025年归属于上市公司股东的净利润为1.35 亿元至1.75亿元，同比增长328.83%-455.89%。业绩变动主要原因系公司积极开拓海外市场，实现海外 收入强劲增长，推动营业收入持续增长，带动净利润大幅上升。 （文章来源：每日经济新闻） ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於香港註冊成立的有限公司） （股份代號：3320） 公告 華潤博雅生物截至2025年12月31日止年度的 業績預告 於 2026 年 1 月 30 日， 華 潤 博雅 生 物 公 佈其 截 至 2025 年 12 月31 日 止年 度 的 業績 預 告。 華潤博雅生物製藥集團股份有限公司（「華潤博雅生物」）為一家於中華人民共和國 註 冊 成 立 的 公 司 。 華 潤 博 雅 生 物 的 股 份 於 深 圳 證 券 交 易 所 上 市 。 截 至 本 公 告 日 期，華潤醫藥集團有限公司（「本公司」，連同其附屬公司合稱為「本集團」）間接持 有華潤博雅生物總股本約30.48 %及總股本約41.79 %表決權，因此華潤博雅生物為 本公司的附屬公司。 於 2026 年 1 月 30 日 ， 華 潤 博 雅 生 物 公 佈 其 截 至 2025 ...

近日，中慧生物-B(02627)迎来又一项里程碑式进展——全国首款且唯一的全人群三价流感病毒亚单位 疫苗成功获批上市。 此前，公司的四价流感亚单位疫苗(慧尔康欣®)已率先实现全人群覆盖，成为中国首款且唯一一款获批 上市的全人群全剂量四价流感病毒亚单位疫苗。此次三价疫苗的成功获批，标志着公司在亚单位流感疫 苗这一优势赛道构建起更加全面的产品矩阵，不仅能够灵活适配多元化的公共卫生需求与市场偏好，也 将为公司业绩的持续兑现与价值重估注入强劲动力。 与此同时，随着中慧生物被纳入新一轮港股通标的名单，市场对公司的关注度亦出现明显提升。自1月 13日以来，公司股价强势上行，突破50港元关口，近十个交易日累计上涨26.47%，成交量同步显著放 大，显示增量资金正持续流入。在产品获批的利好消息驱动下，公司流动性预期持续改善，有望进一步 强化公司在资本市场的吸引力。 前瞻布局亚单位疫苗技术路线 精准填补流感疫苗市场空白 当前，全球流感活动强度持续走高，而我国流感疫苗接种率仍远低于国际水平，这一巨大差距构成了长 期的结构性增长空间。 世卫组织报告显示，自2025年10月以来，全球流感活动强度持续攀升，甲型H3N2亚型流感病毒K亚 ...

Group 1 - Tyligand Bioscience has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [3] - The company, founded in 2017, focuses on discovering and developing innovative cancer therapies and currently holds 97 patents and patent applications, including 25 related to its core product TSN1611 [4] - Tyligand Bioscience has not yet received any market approval for its candidate drugs and has not generated any revenue from product sales [4] Group 2 - As of December 31, 2023, the company reported revenues of 7.856 million RMB, 1.506 million RMB for the nine months ending September 30, 2024, and 11.358 million RMB for the first nine months of 2025 [7] - The company incurred losses of 70.461 million RMB, 28.354 million RMB, and 123.406 million RMB for the respective periods [7] - Revenue sources include providing research and development services and intellectual property licensing [7]

每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 每经AI快讯，科兴制药1月30日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 为1.35亿元~1.75亿元，与上年同期相比，将增加约1.04亿元至1.44亿元，同比增加328.83%~455.89%。 业绩变动主要原因是，2025年，公司积极开拓海外市场，实现了海外收入的强劲增长，推动公司营业收 入持续增长，归属于母公司所有者的净利润及扣除非经常性损益后的净利润均较上年同期实现大幅度提 升。报告期内非经常性损益金额较上年同期变动主要系公司持有的私募基金公允价值变动及处置下属子 公司所致。 （记者 曾健辉） ...

【百利天恒：预计2025年净亏损11亿元 同比转亏】《科创板日报》30日讯，百利天恒(688506.SH)公告 称，预计2025年度归属于上市公司股东的净利润为-11.00亿元左右，上年同期为盈利37.08亿元，同比转 亏。报告期内，公司持续加大研发投入，导致研发投入同比增幅较大。截至报告期末，公司共有17款创 新药处于临床试验阶段（其中6款创新药处于全球临床试验）。公司正在全球范围内开展100余项创新药 临床试验。核心产品iza-bren（EGFR×HER3 双抗ADC）两个适应症——用于治疗局部晚期或转移性鼻 咽癌、用于治疗复发性或转移性食管鳞癌——的上市申请（NDA）已获得国家药品监督管理局药品审 评中心（CDE）受理且被纳入优先审评程序。报告期内收入下降主要原因为上年同期收到BMS首付款 所确认的知识产权收入大于报告期内确认的里程碑收入。 转自：智通财经 ...

南财智讯1月30日电，荣昌生物发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润约为 71,600万元，实现扭亏为盈；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润约为 7,850万元，实现扭亏为盈。本期业绩变化的主要原因：（一）主营业务的影响：本年度，公司核心产 品泰它西普、维迪西妥单抗国内销售收入实现快速增长，成为业绩核心增长引擎；同时，公司成功达成 重磅合作，授予VorBiopharmaInc泰它西普除大中华区以外全球范围内的独家开发与商业化权利，技术 授权收入大幅增加，部分海外研发投入由授权方承担。此外，公司通过优化管理、迭代生产工艺等举 措，降低了产品单位生产成本，提升了产品毛利率，另外，销售费用率明显下降。综合多方面积极因 素，公司盈利效率大幅改善，预计2025年度净利润将实现扭亏为盈。（二）非经常性损益的影响：本年 度自上述授权交易取得的认股权证公允价值变动属于非经常性损益，在扣除非经常性损益的影响后，预 计公司2025年度归属于上市公司股东的扣除非经常性损益后的净利润实现扭亏为盈。 ...

Core Viewpoint - Shenzhou Cell has released its annual performance forecast, expecting a net profit attributable to shareholders of the listed company to be between -520 million yuan and -580 million yuan for the year 2025, indicating a significant year-on-year decrease in net profit [1] Financial Performance - The expected net profit excluding non-recurring gains and losses for 2025 is projected to be between -503 million yuan and -563 million yuan [1] - The company's overall operating revenue is expected to decline compared to the previous year due to significant drops in sales revenue of its core product, Anjiah [1] Factors Affecting Performance - The decline in sales revenue is attributed to the ongoing deepening of industry medical insurance cost control policies and multiple price reductions of the core product [1] - To facilitate market access and channel development for newly approved products during the reporting period, the company has increased its upfront commercialization investments, including academic promotion and sales team formation, leading to a noticeable short-term increase in sales expenses [1] - The company continues to adhere to a research and development strategy of advancing multiple product pipelines, with several ongoing projects entering critical confirmatory clinical trial stages, resulting in sustained high levels of R&D investment that impact current profitability [1]

Core Viewpoint - Chengdu Kanghua Biological Products Co., Ltd. plans to acquire 100% equity of Naimixin (Shanghai) Biotechnology Co., Ltd. through phased capital increase and equity transfer, aiming to integrate Naimixin's mRNA vaccine technology platform to accelerate its new generation vaccine R&D pipeline [1][2]. Group 1: Acquisition Details - The acquisition will proceed in three phases, starting with an investment of up to 120 million yuan for a 27.27% stake in Naimixin [1]. - Subsequent phases will depend on the clinical progress of Naimixin's core product, the RSV mRNA vaccine, and the development milestones of the HPV therapeutic vaccine project [1][2]. Group 2: Naimixin's Technology and Products - Naimixin has developed a comprehensive mRNA drug technology system covering sequence design, delivery systems, and production processes, with its core product being an RSV mRNA vaccine currently in Phase I clinical trials [2]. - The RSV vaccine utilizes a self-developed LNP delivery system and has shown over five times the neutralizing antibody levels compared to traditional inactivated vaccines in preclinical studies [2]. Group 3: Valuation and Milestones - The transaction employs a phased valuation linked to R&D progress, with pre-investment valuations set at a maximum of 320 million yuan, 440 million yuan, and 830 million yuan for each phase [3]. - The final transaction will be directly tied to clinical data from the RSV vaccine and results from the HPV therapeutic vaccine's dose escalation trials [3]. Group 4: Strategic Implications - This acquisition is the first significant merger since a state-owned investment group became the controlling shareholder of Kanghua Biological, potentially providing stronger financial and policy support for innovative drug development [3]. - The domestic market currently lacks a domestic RSV vaccine, and successful development of Naimixin's RSV mRNA vaccine could fill this market gap, marking a critical step in Kanghua Biological's strategic positioning in the biopharmaceutical frontier technology sector [3].

Group 1 - New CEO and Secretary appointed at XinNuoWei, both born in the 1990s, leading to a negative market reaction with a stock price drop of up to 18% [1][10] - The company announced a significant expected net profit loss for 2025, projecting a decline of 416% to 575% compared to 2024 [1][12] - The new CEO, Dai Long, has been with the company since 2016 and previously held multiple roles, while the new Secretary, Xu Wen, has a master's degree and will also serve as a board member [2][7] Group 2 - XinNuoWei's main business focuses on biopharmaceuticals and functional foods, with recent developments in ADC, mRNA vaccines, and antibody drugs [12] - The projected net profit for 2025 is expected to be between -1.7 billion to -2.55 billion, marking a significant decline from a profit of 537.26 million in 2024 [12][13] - The decline in performance is attributed to increased R&D expenses, the acquisition of a controlling stake in a subsidiary, and reduced profit margins in the functional raw materials segment [14]